灯盏生脉胶囊联合瑞舒伐他汀治疗高血压合并高脂血症的疗效及对血清炎性因子水平的影响

Efficacy of Dengzhan Shengmai Capsules Combined with Rosuvastatin on Hypertension Complicated with Hyperlipidemia and Its Effect on the Level of Serum Inflammatory Factors

目的探讨灯盏生脉胶囊联合瑞舒伐他汀治疗高血压合并高脂血症的临床疗效,及其对血清中超敏C反应蛋白(hs-CRP)和白细胞介素6(IL-6)水平的影响。方法选择医院2014年4月至2015年9月收治的高血压合并高脂血症患者58例,按随机数字表法分为对照组和研究组,各29例。对照组患者给予瑞舒伐他汀治疗,研究组患者在对照组治疗基础上加用灯盏生脉胶囊,两组疗程均为4个月。测定治疗前后血压、血脂、血清hs-CRP及IL-6水平,对比两组患者的疗效和不良反应发生情况。结果治疗后,研究组患者的血压和血脂改善情况明显优于对照组(P<0.05);两组患者血清中hs-CRP和IL-6水平均明显下降,且研究组均显著低于对照组(P<0.05);研究组不良反应发生率为13.79%,明显低于对照组的20.69%(P<0.05)。结论灯盏生脉胶囊联合瑞舒伐他汀治疗高血压合并高脂血症临床疗效较好,同时可降低不良反应发生的风险,值得临床推广。

Objective To explore the clinical efficacy of Dengzhan Shengmai Capsules combined with Rosuvastatin therapy for hyperten- sion complicated with hyperlipidemia and its effect on the levels of hypcr- sensitive C- reactive protein（hs- CRP） and interleukin（IL）-6. Methods 58 patients with hypertension combined hyperlipidemia from April 2014 to September 2015 in the hospital were divided into the control group and the research group according to the random indicator method,29 cases in each group. The control group was giv- en Rosuvastatin,while the research group was given Dengzhan Shengmai Capsules combined with Rosuvastatin. The treatment course was 4 months. The blood pressure, blood ]ipids and the level of hs- CRP and IL- 6 of patients were measured before and after the treat- ment respectively. The clinical efficacy and adverse reactions of patients after treatment were compared. Results After treatment, the im- proved situation of blood pressure and blood lipid in research group were better than those of control group（P 〈 0. 05）;the levels of serum hs- CRP and IL-6 of two groups significantly decreased, meanwhile the levels of hs- CRP and IL- 6 of research group were significantly lower than those of the control group（P 〈 0.05）;the incidence of adverse reactions of research was 13.79% ,which was significantly lower than 20. 69% of the control group（ P 〈 0. 05）. Conclusion Dengzhan Shengmai Capsules combined with rosuvastatin has better clinical efficacy on hypertension complicated with hyperlipidemia, and reduce the risk of adverse reactions,which is worthy of clinical promotion.